US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LB Pharmaceuticals

23.82

-0.0400-0.17%

Post-market: 23.820.00000.00%17:43 EST

Volume:263.84K

Turnover:6.29M

Market Cap:681.39M

PE:-32.05

High:24.53

Open:24.03

Low:23.17

Close:23.86

52wk High:24.95

52wk Low:13.36

Shares:28.61M

Float Shares:19.00M

Volume Ratio:1.32

T/O Rate:1.39%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7433

EPS(LYR):-250.6146

ROE:--

ROA:--

PB:2.20

PE(LYR):-0.10

Loading ...

Overview Company News Filings

LB Pharmaceuticals Raises $100 Million in Private Placement with Shares and Pre-Funded Warrants Issued

Lb Pharmaceuticals Announces $100.0 Million Private Placement

THOMSON REUTERS

Lb Pharmaceuticals Inc - Proceeds to Fund Phase 2 Trial for Lb-102

THOMSON REUTERS

Press Release: LB Pharmaceuticals Announces $100.0 Million Private Placement

LB Pharmaceuticals Advances LB-102 Into Long-Term Phase 3 Safety Study for Schizophrenia

Roth MKM Keeps Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX)

LB Pharmaceuticals Launches Phase 2 Trial of LB-102 for Bipolar Depression

Lb Pharmaceuticals Initiates Phase 2 Illuminate-1 Trial in Bipolar Depression, Expanding Lb-102 Development Program

THOMSON REUTERS

Lb Pharmaceuticals Inc - Topline Results Expected in First Quarter of 2028

THOMSON REUTERS

LB Pharmaceuticals Advances LB-102 Into Phase 3, Setting Up a Key Schizophrenia Catalyst for Investors

LB Pharmaceuticals Names Minako Pazdera as General Counsel

Lb Pharmaceuticals Appoints Minako Pazdera, J.d., Ph.d. as General Counsel

THOMSON REUTERS

LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

LB Pharmaceuticals Grants Equity Awards to New Senior Executives

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Roth Capital Initiates Coverage on LB Pharmaceuticals With Buy Rating

MT Newswires Live

LB Pharmaceuticals initiated with a Buy at Roth Capital

LB Pharmaceuticals, Inc. (LBRX) Receives a New Rating from Roth MKM

Lb Pharmaceuticals Strengthens Leadership Team With Key Appointments in Corporate Affairs and People & Culture

THOMSON REUTERS

Press Release: LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LBRX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LBRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","market":"US","secType":"STK","nameCN":"LB Pharmaceuticals","latestPrice":23.82,"timestamp":1770411600000,"preClose":23.86,"halted":0,"volume":263835,"hourTrading":{"tag":"盘后","latestPrice":23.82,"preClose":23.82,"latestTime":"17:43 EST","volume":9312,"amount":221811.84,"timestamp":1770417821492,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0016764459346185728,"floatShares":19000000,"shares":28605700,"eps":-0.743267,"marketStatus":"Market Closed","change":-0.04,"latestTime":"02-06 16:00:00 EST","open":24.03,"high":24.53,"low":23.165,"amount":6290198.40735,"amplitude":0.057209,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.743267,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1757563200000,"exchange":"NASDAQ","adjPreClose":23.86,"preHourTrading":{"tag":"盘前","latestPrice":24.2,"preClose":23.86,"latestTime":"09:27 EST","volume":68,"amount":1640.81994,"timestamp":1770388078620,"change":0.34,"changeRate":0.01425,"amplitude":0.047779},"postHourTrading":{"tag":"盘后","latestPrice":23.82,"preClose":23.82,"latestTime":"17:43 EST","volume":9312,"amount":221811.84,"timestamp":1770417821492,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3233899984021313},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","floatShares":19000000,"roa":"--","roe":"--","lyrEps":-250.614601,"volumeRatio":1.3233899984021313,"shares":28605700,"dividePrice":0,"high":24.53,"amplitude":0.057209,"preClose":23.86,"low":23.165,"week52Low":13.36,"pbRate":"2.20","week52High":24.9499,"institutionHeld":0,"latestPrice":23.82,"eps":-0.743267,"divideRate":0,"volume":263835,"delay":0,"ttmEps":-0.743267,"open":24.03,"prevYearClose":22.26,"prevWeekClose":21.45,"prevMonthClose":21.45,"prevQuarterClose":22.26,"fiveDayClose":21.45,"twentyDayClose":20.8,"sixtyDayClose":14.61},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LBRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LBRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LBRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1768021200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LBRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LBRX","date":"2026-02-06","current":-32.047703,"percent":0.009804,"low":-32.168769,"twenty":-28.673392,"median":-21.418938,"eighty":-12.137776,"high":-0.410019,"avg":-20.505255,"sd":7.741296,"marketCap":603636573},"quantilePoints":[{"date":"2025-09-12","current":-13.187639,"twenty":-10.632115,"median":-6.798829,"eighty":-2.965543,"marketCap":388099031},{"date":"2025-09-19","current":-12.217088,"twenty":-12.798201,"median":-12.438246,"eighty":-12.070666,"marketCap":359536683},{"date":"2025-09-26","current":-11.40109,"twenty":-12.682283,"median":-12.163705,"eighty":-11.408716,"marketCap":335522685},{"date":"2025-10-03","current":-11.790024,"twenty":-12.394014,"median":-12.03406,"eighty":-11.475827,"marketCap":346968609},{"date":"2025-10-10","current":-11.927294,"twenty":-12.217088,"median":-11.973051,"eighty":-11.471251,"marketCap":351008347},{"date":"2025-10-17","current":-12.506882,"twenty":-12.401641,"median":-12.018808,"eighty":-11.491079,"marketCap":368065019},{"date":"2025-10-24","current":-12.079817,"twenty":-12.247593,"median":-12.026434,"eighty":-11.561239,"marketCap":355496945},{"date":"2025-10-31","current":-12.415368,"twenty":-12.43367,"median":-12.041687,"eighty":-11.652753,"marketCap":365371860},{"date":"2025-11-07","current":-18.511527,"twenty":-12.493155,"median":-12.14464,"eighty":-11.774771,"marketCap":348090759},{"date":"2025-11-14","current":-20.046619,"twenty":-12.715838,"median":-12.201836,"eighty":-11.777822,"marketCap":376956619},{"date":"2025-11-21","current":-21.244034,"twenty":-16.587413,"median":-12.217088,"eighty":-11.811377,"marketCap":399472820},{"date":"2025-11-28","current":-23.934856,"twenty":-18.511527,"median":-12.278098,"eighty":-11.89679,"marketCap":450071024},{"date":"2025-12-05","current":-25.899155,"twenty":-20.625145,"median":-12.354359,"eighty":-11.912042,"marketCap":487007713},{"date":"2025-12-12","current":-27.217658,"twenty":-21.714928,"median":-12.472564,"eighty":-11.927294,"marketCap":511800833},{"date":"2025-12-19","current":-26.50459,"twenty":-23.934856,"median":-12.598395,"eighty":-11.934921,"marketCap":498392309},{"date":"2025-12-26","current":-29.599034,"twenty":-25.317938,"median":-12.735666,"eighty":-11.971526,"marketCap":556580244},{"date":"2026-01-02","current":-29.948841,"twenty":-26.033696,"median":-12.811928,"eighty":-12.003556,"marketCap":563158010},{"date":"2026-01-09","current":-27.984542,"twenty":-26.736001,"median":-17.717835,"eighty":-12.027959,"marketCap":526221321},{"date":"2026-01-16","current":-28.76488,"twenty":-26.943194,"median":-18.511527,"eighty":-12.038636,"marketCap":540894800},{"date":"2026-01-23","current":-31.724783,"twenty":-27.597063,"median":-20.046619,"eighty":-12.056939,"marketCap":596552825},{"date":"2026-01-30","current":-28.482344,"twenty":-28.30475,"median":-20.93459,"eighty":-12.092019,"marketCap":535581989},{"date":"2026-02-06","current":-32.101498,"twenty":-28.673392,"median":-21.418938,"eighty":-12.137776,"marketCap":603636573}],"updateTime":1770468599885},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LBRX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609308957","title":"LB Pharmaceuticals Raises $100 Million in Private Placement with Shares and Pre-Funded Warrants Issued","url":"https://stock-news.laohu8.com/highlight/detail?id=2609308957","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609308957?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:04","pubTimestamp":1770296645,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc. has announced the issuance of pre-funded warrants to purchase up to 1,417,107 shares of its common stock as part of a private placement. The pre-funded warrants were offered alongside 3,306,571 shares of common stock to select institutional investors. The purchase price for each pre-funded warrant is $21.1699, reflecting the per share purchase price for common stock less the $0.0001 per share exercise price. This private placement is expected to raise approximately $100 million in gross proceeds, with the funds intended to support a Phase 2 trial for LB-102 as an adjunctive treatment for major depressive disorder and for general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceutical","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL60rzkH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX","LU2210149790.SGD","BK4112","SG9999014005.SGD","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","BK4585","LU2095319765.USD","SG9999014021.USD","NDAQ"],"gpt_icon":0},{"id":"2609409370","title":"Lb Pharmaceuticals Announces $100.0 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2609409370","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609409370?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:00","pubTimestamp":1770296401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nTUA35DJXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"gpt_icon":0},{"id":"2609308589","title":"Lb Pharmaceuticals Inc - Proceeds to Fund Phase 2 Trial for Lb-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2609308589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609308589?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:00","pubTimestamp":1770296401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nTUA35DJXK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"2609517308","title":"Press Release: LB Pharmaceuticals Announces $100.0 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2609517308","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609517308?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:00","pubTimestamp":1770296400,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 05, 2026  -- LB Pharmaceuticals Inc  , a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced that it has entered into a securities purchase agreement to sell 3,306,571 shares of its common stock and pre-funded warrants to purchase up to 1,417,107 shares of its common stock to a select group of institutional investors in a private placement. The purchase price of each share of common stock is $21.17. The purchase price of each pre-funded warrant is $21.1699, which represents the per share purchase price for the common stock less the $0.0001 per share exercise price for such pre-funded warrant. LB Pharmaceuticals anticipates the gross proceeds from the private placement to be approximately $100.0 million, before deducting any transaction-related expenses. The private placement is expected to close on or about February 6, 2026, subject to the satisfaction of customary clo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","LB","BK4213","BK4233","BK4007"],"gpt_icon":0},{"id":"2606736790","title":"LB Pharmaceuticals Advances LB-102 Into Long-Term Phase 3 Safety Study for Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2606736790","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606736790?lang=en_us&edition=fundamental","pubTime":"2026-01-28 00:31","pubTimestamp":1769531479,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals, Inc. ($LBRX) announced an update on their ongoing clinical study. Study Overview LB Pharmaceuticals, Inc. (LBRX) has launched a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lb-pharmaceuticals-advances-lb-102-into-long-term-phase-3-safety-study-for-schizophrenia?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lb-pharmaceuticals-advances-lb-102-into-long-term-phase-3-safety-study-for-schizophrenia?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4233","BK4213","LBRX","LB","BK4007"],"gpt_icon":0},{"id":"2606173393","title":"Roth MKM Keeps Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606173393","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606173393?lang=en_us&edition=fundamental","pubTime":"2026-01-27 22:55","pubTimestamp":1769525759,"startTime":"0","endTime":"0","summary":"Roth MKM analyst Boobalan Pachaiyappan maintained a Buy rating on LB Pharmaceuticals, Inc. today and set a price target of $31.00. Pachaiyappan cov...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roth-mkm-keeps-their-buy-rating-on-lb-pharmaceuticals-inc-lbrx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roth-mkm-keeps-their-buy-rating-on-lb-pharmaceuticals-inc-lbrx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LBRX","LB"],"gpt_icon":0},{"id":"2606489212","title":"LB Pharmaceuticals Launches Phase 2 Trial of LB-102 for Bipolar Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2606489212","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606489212?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:02","pubTimestamp":1769432528,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc. has announced the initiation of a Phase 2 clinical trial, ILLUMINATE-1, to evaluate the efficacy and safety of LB-102 in patients with bipolar depression. LB-102 is a novel, once-daily oral small molecule and a selective antagonist of D2, D3, and 5HT7 receptors. The randomized, double-blind, placebo-controlled trial will enroll approximately 320 patients with bipolar 1 depression across 30 sites in the U.S., with participants receiving either 25 mg or 50 mg doses of LB-102 or placebo over six weeks. The primary endpoint is the Montgomery-sberg Depression Rating Scale -10 at week six. Secondary endpoints include MADRS-6, CGI-BP, cognition, anhedonia, safety, and tolerability. Topline results from the trial are expected in the first quarter of 2028. Results have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL732HP8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0314104364.USD","BK4112","BK4585","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014021.USD","SG9999014013.SGD","LBRX","BK4007","IE00BKPKM429.USD","LU2210150020.SGD","NDAQ","SG9999014005.SGD","IE00BGHQF748.EUR","SG9999014039.USD"],"gpt_icon":0},{"id":"2606341248","title":"Lb Pharmaceuticals Initiates Phase 2 Illuminate-1 Trial in Bipolar Depression, Expanding Lb-102 Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2606341248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606341248?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:00","pubTimestamp":1769432403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nTUA2MQVVK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"2606248302","title":"Lb Pharmaceuticals Inc - Topline Results Expected in First Quarter of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2606248302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606248302?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:00","pubTimestamp":1769432403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nTUA2MQVVK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"2605840414","title":"LB Pharmaceuticals Advances LB-102 Into Phase 3, Setting Up a Key Schizophrenia Catalyst for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2605840414","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605840414?lang=en_us&edition=fundamental","pubTime":"2026-01-24 00:33","pubTimestamp":1769185981,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals, Inc. ($LBRX) announced an update on their ongoing clinical study. Study Overview LB Pharmaceuticals, Inc. is launching a late-s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lb-pharmaceuticals-advances-lb-102-into-phase-3-setting-up-a-key-schizophrenia-catalyst-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lb-pharmaceuticals-advances-lb-102-into-phase-3-setting-up-a-key-schizophrenia-catalyst-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LB","BK4211","BK4213","BK4233","ISBC","BK4007","LBRX"],"gpt_icon":0},{"id":"2605102248","title":"LB Pharmaceuticals Names Minako Pazdera as General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2605102248","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605102248?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:01","pubTimestamp":1769000469,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc. has appointed Dr. Minako Pazdera as General Counsel. Dr. Pazdera brings over 25 years of experience in corporate governance, intellectual property, and strategic transactions. She previously served as General Counsel and Corporate Secretary at Kardigan and Carmot Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on January 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL2fD717:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014005.SGD","SG9999014021.USD","IE00B64PRP62.GBP","BK4007","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210150020.SGD","LBRX","SG9999014013.SGD","BK4585","BK4588","LU2210149790.SGD","NDAQ","SG9999014039.USD","BK4112"],"gpt_icon":0},{"id":"2605710246","title":"Lb Pharmaceuticals Appoints Minako Pazdera, J.d., Ph.d. as General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2605710246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605710246?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:00","pubTimestamp":1769000406,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nTUA1LH1R2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"2605107699","title":"LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2605107699","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605107699?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:00","pubTimestamp":1769000400,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan.  21, 2026  (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/21/3222743/0/en/LB-Pharmaceuticals-Appoints-Minako-Pazdera-J-D-Ph-D-as-General-Counsel.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","LB","BK4233","BK4213","BK4007"],"gpt_icon":0},{"id":"2603526551","title":"LB Pharmaceuticals Grants Equity Awards to New Senior Executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2603526551","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603526551?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:05","pubTimestamp":1768251959,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc. has granted equity awards to two new executives, Ellen Rose, Senior Vice President of Corporate Affairs, and Lindsay Beaupre, Senior Vice President of People and Culture. Ellen Rose received options to purchase 100,000 shares of common stock, while Lindsay Beaupre received options for 75,000 shares. The options have a ten-year term and an exercise price of $20.73 per share, reflecting the closing price on the grant date. The options vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting monthly over the following three years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief v","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLbDm04g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014021.USD","LBRX","IE00BKPKM429.USD","NDAQ","LU0314104364.USD","SG9999014039.USD","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014005.SGD","BK4585","BK4007","BK4112"],"gpt_icon":0},{"id":"2603576526","title":"LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603576526","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603576526?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:05","pubTimestamp":1768251900,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan.  12, 2026  (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Ellen Rose, the new Senior Vice Presi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3217344/0/en/LB-Pharmaceuticals-Reports-Inducement-Grant-to-New-Employee-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","BK4007","LB","LBRX","BK4233"],"gpt_icon":0},{"id":"2602872373","title":"Roth Capital Initiates Coverage on LB Pharmaceuticals With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2602872373","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602872373?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:15","pubTimestamp":1767960941,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc (LBRX) has an average rating of Buy and mean price target of $44.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LBRX","LB"],"gpt_icon":0},{"id":"2602321369","title":"LB Pharmaceuticals initiated with a Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2602321369","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602321369?lang=en_us&edition=fundamental","pubTime":"2026-01-09 17:30","pubTimestamp":1767951020,"startTime":"0","endTime":"0","summary":"Roth Capital initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $31 price target The company’s LB-102, a Phase 3-ready schizophr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-initiated-with-a-buy-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-initiated-with-a-buy-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LBRX","BK4007","BK4213","BK4233","LB"],"gpt_icon":0},{"id":"2602534160","title":"LB Pharmaceuticals, Inc. (LBRX) Receives a New Rating from Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2602534160","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602534160?lang=en_us&edition=fundamental","pubTime":"2026-01-09 13:35","pubTimestamp":1767936919,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals, Inc. received a Buy rating and a $31.00 price target from Roth MKM analyst Boobalan Pachaiyappan today. According to TipRanks, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lb-pharmaceuticals-inc-lbrx-receives-a-new-rating-from-roth-mkm-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lb-pharmaceuticals-inc-lbrx-receives-a-new-rating-from-roth-mkm-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LBRX","LB"],"gpt_icon":0},{"id":"2601894860","title":"Lb Pharmaceuticals Strengthens Leadership Team With Key Appointments in Corporate Affairs and People & Culture","url":"https://stock-news.laohu8.com/highlight/detail?id=2601894860","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601894860?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:00","pubTimestamp":1767700805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA7PBCHK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"2601894562","title":"Press Release: LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture","url":"https://stock-news.laohu8.com/highlight/detail?id=2601894562","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601894562?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:00","pubTimestamp":1767700800,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan. 06, 2026  -- LB Pharmaceuticals, Inc  , a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture.Ms. Beaupre is a strategic and results-driven People and Culture executive with an extensive track record in the biotech and financial services sectors, driving organizational effectiveness, leadership capability, and cultural clarity. She partners closely with executive teams to build high-performing organizations during periods of growth and change. Most recently Ms. Beaupre was the Chief Administrative Officer at Lyndra Therapeutics, where she led enterprise-wide people and operational initiatives. Earlier in her career she held senior people leadership roles at prominent biotech companies such as Vertex Pharmaceuticals and Immunoge","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LB","LBRX","TISI","BK4233","BK4120","BK4213","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":61,"code":"91000000","status":"200"}]}}